Similar articles

• Neurological effects of MIF-1, MSH, and opiate peptides in clinical studies.

  Kastin AJ, Ehrensing RH, Olson RD, Coy DH. Kastin AJ, et al. Int J Neurol. 1980;14(2-4):205-9. Int J Neurol. 1980. PMID: 6152908 Review. No abstract available.
• [Physiological trials with MIF-I in Parkinson's disease (author's transl)].

  Gonce M, Barbeau A. Gonce M, et al. Rev Neurol (Paris). 1978 Feb;134(2):141-9. Rev Neurol (Paris). 1978. PMID: 29330 Clinical Trial. French.
• [MIF (melanocyte-stimulating hormone release-inhibiting factor) and Parkinson's disease].

  Carolei A, Meco G, Casacchia M, Agnoli A. Carolei A, et al. Acta Neurol (Napoli). 1976 Jul-Aug;31(4):475-8. Acta Neurol (Napoli). 1976. PMID: 16441 Clinical Trial. Italian. No abstract available.
• The antiparkinsonian activity of dopamine agonists and their interaction with central dopamine receptor subtypes.

  Goldstein M, Lieberman AN, Takasugi N, Shimizu Y, Kuga S. Goldstein M, et al. Adv Neurol. 1990;53:101-6. Adv Neurol. 1990. PMID: 1978511 Review. No abstract available.
• Pharmacological basis of therapeutics: dopamine receptors.

  Heikkila RE. Heikkila RE. J Med Soc N J. 1984 Dec;81(12):1084-6. J Med Soc N J. 1984. PMID: 6150999 No abstract available.